LRRK2-IN-1
Code | Size | Price |
---|
TAR-T2246-5mg | 5mg | £119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2246-10mg | 10mg | £140.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2246-1mL | 1 mL * 10 mM (in DMSO) | £142.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2246-25mg | 25mg | £213.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2246-50mg | 50mg | £328.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2246-100mg | 100mg | £523.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.
CAS:
1234480-84-2
Formula:
C31H38N8O3
Molecular Weight:
570.698
Pathway:
Apoptosis; Autophagy; Cell Cycle/Checkpoint
Purity:
0.9844
SMILES:
COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1
Target:
Apoptosis; LRRK2; CDK
References
1. Deng X, et al. Nat Chem Biol. 2011, 7(4), 203-205.
2. Yao C, et al. Hum Mol Genet. 2013, 22(2), 328-344.
3. Caesar M, et al. Neurobiol Dis. 2013, 54, 280-288.
4. Weygant N, et al. Mol Cancer. 2014, 13, 103.
5. Yan R, Li J J, Zhou Y, et al. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer[J]. Life Sciences. 2020, 241: 117150.